Two Reflections about Amadori Products: Biomarkers or Therapeutic Targets for Coronary Artery Disease?  
Álvarez, E. (Santiago de Compostela)

Osteoprotegerin and ST Segment Myocardial Infarction: A Novel Risk Marker but Not for Routine Use at Present  
Thadani, U. (Oklahoma City, Okla.)

TRAIL, a New Weapon against Neointimal Hyperplasia  
Secchiero, P. (Ferrara); Zauli, G. (Trieste)

Bovine Aortic Arch: Normal Variant or a Marker of Aortopathy?  
Angouras, D.C. (Athens); Boudoulas, K.D. (Columbus, Ohio); Boudoulas, H. (Athens/Columbus, Ohio)

Carotid Intima-Media Thickness Provides Evidence that Ascending Aortic Aneurysm Protects against Systemic Atherosclerosis  
Hung, A.; Zafar, M.; Mukherjee, S.; Tranquilli, M.; Scoutt, L.M.; Elefteriades, J.A. (New Haven, Conn.)

Glycated Albumin Is Superior to Hemoglobin A₁c for Evaluating the Presence and Severity of Coronary Artery Disease in Type 2 Diabetic Patients  
Shen, Y.; Pu, L.J.; Lu, L.; Zhang, Q.; Zhang, R.Y.; Shen, W.F. (Shanghai)

Inverse Association of Coronary Soluble Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (sTRAIL) Levels to In-Stent Neointimal Hyperplasia  

‘Bovine’ Aortic Arch – A Marker for Thoracic Aortic Disease  
Hornick, M. (Philadelphia, Pa.); Moomiaie, R.; Mojibian, H. (New Haven, Conn.); Ziganshin, B. (New Haven, Conn./Kazan); Almuwaqqat, Z. (New Haven, Conn.); Lee, E.S. (Los Angeles, Calif.); Rizzo, J.A. (Stony Brook, N.Y.); Tranquilli, M.; Elefteriades, J.A. (New Haven, Conn.)

Intracoronary Monocyte Chemoattractant Protein 1 and Vascular Endothelial Growth Factor Levels Are Associated with Necrotic Core, Calcium and Fibrous Tissue Atherosclerotic Plaque Components: An Intracoronary Ultrasound Radiofrequency Study  
Fuchs, S. (Petach Tikva/Tel Aviv); Lavi, I.; Tzang, O. (Tel Aviv); Bessler, H. (Petach Tikva/Tel Aviv); Brosh, D.; Bental, T.; Dvir, D. (Petach Tikva); Einav, S. (Tel Aviv); Kornowski, R. (Petach Tikva/Tel Aviv)

(Continued on inside front cover)
Novel Insights from Clinical Experience

103 A Case of Fatal Fulminant Myocarditis Presenting as an Acute ST-Segment Elevation Myocardial Infarction and Persistent Ventricular Tachyarrhythmia Associated with Influenza A (H1N1) Virus in a Previously Healthy Pregnant Woman
Ona, M.A.; Bashari, D.R.; Tharayil, Z.; Charlot, A.; Hoskins, I.; Timoney, M.; Usmani, S.; Royzman, R. (Brooklyn, N.Y.)

108 An Infant with Heart Failure due to Ventricular Dyssynchrony and Refractory Tachycardia Caused by a Right Anterolateral Accessory Pathway

Letters to the Editor

78 Exercise Training for Refractory Angina: Improving the Coronary Collateral Circulation
Froehlich, G. (London/Zurich); Crake, T.; Meier, P. (London)

80 Author's Reply
Asbury, E.A.; Webb, C.M.; Probert, H.; Wright, C.; Barbir, M.; Fox, K.; Collins, P. (London)
**Editorial Board**

<table>
<thead>
<tr>
<th>Name</th>
<th>City/State</th>
</tr>
</thead>
<tbody>
<tr>
<td>C.A. Hochreiter</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>M. Hori</td>
<td>Osaka</td>
</tr>
<tr>
<td>S.K.S. Huang</td>
<td>Temple, Tex.</td>
</tr>
<tr>
<td>B.K. Kantharia</td>
<td>Houston, Tex.</td>
</tr>
<tr>
<td>J.S. Karliner</td>
<td>San Francisco, Calif.</td>
</tr>
<tr>
<td>R.E. Kerber</td>
<td>Iowa City, Iowa</td>
</tr>
<tr>
<td>N.Z. Kerin</td>
<td>Detroit, Mich.</td>
</tr>
<tr>
<td>A. Kimchi</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>R.N. Kitsis</td>
<td>Bronx, N.Y.</td>
</tr>
<tr>
<td>P. Kligfield</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>X. Kong</td>
<td>Nanjing</td>
</tr>
<tr>
<td>M.A. Konstam</td>
<td>Boston, Mass.</td>
</tr>
<tr>
<td>J.B. Kostis</td>
<td>New Brunswick, N.J.</td>
</tr>
<tr>
<td>P. Kowey</td>
<td>Wynnewood, Pa.</td>
</tr>
<tr>
<td>K.H. Krieger</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>H. Krum</td>
<td>Melbourne</td>
</tr>
<tr>
<td>E. Kuschnir</td>
<td>Córdoba</td>
</tr>
<tr>
<td>H. Kusuoka</td>
<td>Osaka</td>
</tr>
<tr>
<td>W. Laskey</td>
<td>Albuquerque, N.Mex.</td>
</tr>
<tr>
<td>J.M. Lazar</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>C.V. Leier</td>
<td>Columbus, Ohio</td>
</tr>
<tr>
<td>M.C. Limacher</td>
<td>Gainesville, Fla.</td>
</tr>
<tr>
<td>R.J. Lipicky</td>
<td>North Potomac, Md.</td>
</tr>
<tr>
<td>T.F. Lüscher</td>
<td>Zurich</td>
</tr>
<tr>
<td>F.I. Marcus</td>
<td>Tuscon, Ariz.</td>
</tr>
<tr>
<td>A.J. Marian</td>
<td>Houston, Tex.</td>
</tr>
<tr>
<td>J.D. Marmur</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>F.A. Martinez</td>
<td>Córdoba</td>
</tr>
<tr>
<td>M.G. Massad</td>
<td>Chicago, Ill.</td>
</tr>
<tr>
<td>P. Meier</td>
<td>London</td>
</tr>
<tr>
<td>E.H. Messerli</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>J. Midwall</td>
<td>Atlantis, Fla.</td>
</tr>
<tr>
<td>R.M. Mills</td>
<td>Raritan, N.J.</td>
</tr>
<tr>
<td>J.E. Mitchell</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>R.J. Myerburg</td>
<td>Miami, Fla.</td>
</tr>
<tr>
<td>J. Narula</td>
<td>Orange, Calif.</td>
</tr>
<tr>
<td>J.V. Nixon</td>
<td>Richmond, Va.</td>
</tr>
<tr>
<td>H. Oh</td>
<td>Okayama</td>
</tr>
<tr>
<td>P. Piobarot</td>
<td>Quebec</td>
</tr>
<tr>
<td>B. Pitt</td>
<td>Ann Arbor, Mich.</td>
</tr>
<tr>
<td>G.M. Pohost</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>E.N. Prystowsky</td>
<td>Indianapolis, Ind.</td>
</tr>
<tr>
<td>N. Reichek</td>
<td>Roslyn, N.Y.</td>
</tr>
<tr>
<td>W.J. Remme</td>
<td>Rhoon</td>
</tr>
<tr>
<td>R. Roberts</td>
<td>Ottawa</td>
</tr>
<tr>
<td>W.C. Roberts</td>
<td>Dallas, Tex.</td>
</tr>
<tr>
<td>R. Rosenhek</td>
<td>Vienna</td>
</tr>
<tr>
<td>J.N. Ruskin</td>
<td>Boston, Mass.</td>
</tr>
<tr>
<td>F. Ruschitzka</td>
<td>Zurich</td>
</tr>
<tr>
<td>M.E. Sarano</td>
<td>Rochester, Minn.</td>
</tr>
<tr>
<td>V.L. Serebruany</td>
<td>Towson, Md.</td>
</tr>
<tr>
<td>M.R. Starling</td>
<td>Mesa, Ariz.</td>
</tr>
<tr>
<td>P. Supino</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>J.L. Swain</td>
<td>La Jolla, Calif.</td>
</tr>
<tr>
<td>K. Swedberg</td>
<td>Göteborg</td>
</tr>
<tr>
<td>A.J. Tajik</td>
<td>Rochester, Minn.</td>
</tr>
<tr>
<td>L. Tavazzi</td>
<td>Cotignola</td>
</tr>
<tr>
<td>J.R. Teerlink</td>
<td>San Francisco, Calif.</td>
</tr>
<tr>
<td>M. Tendera</td>
<td>Katowice</td>
</tr>
<tr>
<td>U. Thadani</td>
<td>Oklahoma City, Okla.</td>
</tr>
<tr>
<td>K. Thygesen</td>
<td>Aarhus</td>
</tr>
<tr>
<td>N.K. Wenger</td>
<td>Atlanta, Ga.</td>
</tr>
<tr>
<td>W.B. White</td>
<td>Farmington, Conn.</td>
</tr>
<tr>
<td>J.T. Willerson</td>
<td>Houston, Tex.</td>
</tr>
<tr>
<td>R.G. Williams</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>K.K.-Y. Wu</td>
<td>Zhunan Town</td>
</tr>
<tr>
<td>F. Zannad</td>
<td>Nancy</td>
</tr>
<tr>
<td>B.L. Zaret</td>
<td>New Haven, Conn.</td>
</tr>
<tr>
<td>D.P. Zipes</td>
<td>Indianapolis, Ind.</td>
</tr>
</tbody>
</table>
Guidelines for Authors

Submission

"Cardiology" publishes original reports in research and observations pertaining to cardiovascular physiology, epidemiology, pharmacology, disease and therapy. Only original papers written in English are considered. The articles should be readily comprehensible to a reader who is fluent in English. Therefore, all manuscripts originating from non-English-speaking authors must be edited prior to submission to assure that standard English grammar and usage are observed. This may require help from a colleague or other editorial assistant. It must be made clear that the manuscript must be written in English. Submissions that are not edited in this way will not be considered for publication until such editing has been achieved. Manuscripts should be submitted using the online submission website:

www.karger.com/crd

If you have any problems with submission, please contact:

S. Karger AG
Editorial Office ‘Cardiology’
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1343
E-Mail crd@karger.ch

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication and that there are no conflicts of interest, see below. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Main Sections

1. Original Research
2. Original Research – Clinical Trial Design
3. Review
4. Turning Basic Research into Clinical Success
5. Letter to the Editor
6. Novel Insights from Clinical Experience (formerly Case Reports)
7. Short Communications
8. Commentary

Conditions

All manuscripts are subject to editorial review. Manuscripts are reviewed with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Cardiology' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest in Cardiovascular Publications

Declaration of potential conflict of interest should be part of each publication or presentation and be designated as one or more of four categories: (1) No relationship. (2) Relationship with a For Profit Organization. (3) Research relationship with a For Profit or Not For Profit Organization, which should be named. (4) Employee of a For Profit or Not For Profit Organization. For legal reasons, all authors are required during submission of their manuscript to complete and sign a Copyright Transfer & Conflicts of Interest Statement. The corresponding author must ensure that all authors have been asked to sign this form and to disclose any conflicts of interest.

Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Plagiarism

Authors should not appropriate the ideas, language or other elements of the work of others without providing appropriate attribution (i.e. 'plagiarism'). Plagiarism includes, but is not limited to, verbatim copying without quotation marks, close paraphrasing or summarization of sentences or narrative passages without citing source, and duplication of figures, graphs, images or data without acknowledgement of their origins. Authors also should not submit a previously published manuscript or a section of a previously published manuscript, even when re-titled, otherwise re-worded or augmented, without clearly identifying its relation to the author's earlier work (duplicate publication or 'self-plagiarism'). For additional guidance, see Roig M: Plagiarism and self-plagiarism: What every author should know. Biochimica Medica 2010:20:295–300.

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

For submissions to Main Sections 1, 2 and 3:
Original Research, Original Research – Clinical Trial Design, and Review Papers

Abstract: The abstract is an essential and most read part of the paper. It should be printed on a separate page, up to 200 words, factual, free of abbreviations (except as specifically defined within the abstract text at first use) and should be structured as follows:

Objective: Should describe the purpose of the study and the problem addressed; should include at least one sentence providing the rationale or justification for the study.

Methods: Should explain how the study was performed (samples and/or population, procedures, analytical methods).

Results: Should describe the main findings with specific data and their statistical significance, if possible.

Conclusions: Should contain a succinct interpretation of the inferences to be drawn from results.

KARGER

© 2012 S. Karger AG, Basel

The Guidelines for Authors are available at:

www.karger.com/crd_Guidelines

www.karger.com
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at http://www.karger.com/crd/).

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. See also International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author's Choice

With this option the author can choose to make his article freely available online against a one-time fee of CHF 3000.–. This fee is independent of any standard charges for supplementary pages, color images etc. which may apply. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy are available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges

There are no page charges for papers of 6 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 18 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
INTERNATIONAL MEETING ON PULMONARY RARE DISEASES AND ORPHAN DRUGS

PRESIDENT
SERGIO HARARI

MILANO – ITALY
FEBRUARY 8-9, 2013

ORGANIZING SECRETARIAT
VICTORY PROJECT CONGRESSI
Via C. Poma, 2 - 20129 Milan, Italy
Tel. +39 02 89 05 35 24
Fax +39 02 20 13 95
info@victoryproject.it

WWW.PULMONARYRAREDISEASES.COM
Contents

See the journal website for contents
INTERNATIONAL CONGRESS ON UPDATE IN CARDIOLOGY AND CARDIOVASCULAR SURGERY
March 21 - 24, 2013
Maxx Royal Convention Center
Antalya, TURKEY

www.uccvs2013.org
www.tksv.org
79. Jahrestagung

Annual Meeting

Thema: Die Kardiomyopathien
Topic: The Cardiomyopathies

Tagungspräsident/President of the Congress:
Prof. Dr. Hugo A. Katus, Heidelberg

Geschäftsstelle: Achenbachstraße 43 · D-40237 Düsseldorf
Telefon: +49 (0)211 600692-0 · Telefax: +49 (0)211 600692-10
kongress@dgk.org · www.dgk.org
A source of current research, new methods and state-of-the-art reviews in vascular biology and microcirculation

The Journal of Vascular Research publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation.

More information at www.karger.com/jvr

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Selected contributions

- Inhibition of Protein Kinase C β2 Prevents Tumor Necrosis Factor-α-Induced Apoptosis and Oxidative Stress in Endothelial Cells: The Role of NADPH Oxidase Subunits: Deng, B.; Xie, S.; Wang, J. (Guangzhou); Xia, Z. (Wuhan); Nie, R. (Guangzhou)
- Asymmetric Dimethylarginine Reduces Nitric Oxide Donor-Mediated Dilation of Arterioles by Activating the Vascular Renin-Angiotensin System and Reactive Oxygen Species: Veresh, Z. (Valhalla, N.Y./Budapest); Debreczeni, B.; Hamar, J. (Pecs); Raminski, P.M.; Wolin, M.S. (Valhalla, N.Y.); Koller, A. (Valhalla, N.Y./Pecs)
- Development and Characterization of an Animal Model of Severe Pulmonary Arterial Hypertension: Morimatsu, Y. (Kumamoto/Bordeaux); Sakakita, N.; Komohara, Y.; Ohnishi, K. (Kumamoto); Masuda, H. (Pessac); Dahan, D. (Bordeaux); Takeya, M. (Kumamoto); Guilbert, C.; Marthan, R. (Bordeaux)
- Twisted Blood Vessels: Symptoms, Etiology and Biomechanical Mechanisms: Han, H.-C. (San Antonio, Tex.)
- Effect of Cystamine on Blood Pressure and Vascular Characteristics in Spontaneously Hypertensive Rats: Engholm, M.; Eftekhari, A. (Aarhus); Dahan, D. (Bordeaux); Takeya, M. (Kumamoto); Guibert, C.; Marthan, R. (Bordeaux)
- Age-Related Changes in the Elastic Tissue of the Human Aorta: Fritz, O. (Tübingen); Romero, B. (Madrid); Schleicher, M. (Tübingen); Jacob, M.P. (Paris); Oh, D.-Y. (Berlin); Starches, B. (Tyler, Tex.); Schenke-Layland, K. (Tübingen/Stuttgart); Bujan, J. (Madrid); Stock, U.A. (Tübingen)

The Journal of Vascular Research publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation. JVR’s “Vascular update” series regularly presents state of the art reviews on hot topics in vascular biology. Manuscript processing times are, consistent with stringent review, kept as short as possible due to electronic submission. All articles are published online first, ensuring rapid publication. The Journal of Vascular Research is the official journal of the European Society of Microcirculation. A biennial prize is awarded to the authors of the best paper published in the journal over the previous two years, thus encouraging young scientists working in the exciting field of vascular biology to publish their findings.

More information at www.karger.com/jvr

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Journal of Vascular Research
2013: Volume 50
6 issues per volume
Language: English
ISSN 1018–1172 (print)
ISSN 1423–0135 (online)

Listed in bibliographic services, including Current Contents®/Life Sciences, MEDLINE, Biological Abstracts, Chemical Abstracts, EMBASE/Excerpta Medica

More information at www.karger.com/jvr

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Journal of Vascular Research
2013: Volume 50
6 issues per volume
Language: English
ISSN 1018–1172 (print)
ISSN 1423–0135 (online)

Listed in bibliographic services, including Current Contents®/Life Sciences, MEDLINE, Biological Abstracts, Chemical Abstracts, EMBASE/Excerpta Medica
This special issue of Cells Tissues Organs contains a collection of state-of-the-art papers on cardiovascular regenerative medicine. Diseases of the cardiovascular system are the most frequent cause of death, a problem which will further increase due to aging demographics. Therefore, approaches to tissue engineering and regenerative medicine that have the ability to reconstruct functional healthy cardiovascular structures could have a major impact on health care delivery. Current concepts and approaches which have the potential to be critical components of the next generation of therapy to create or repair blood vessels and heart tissues are discussed in this issue. The focus is on cell sources for cardiovascular tissues, niche scaffolds, blood vessels and vascular networks, as well as engineered heart tissues.

This publication is of special importance for scientists and physicians who are interested in vascular tissue engineering, artificial grafting, developmental biology, cardiovascular regenerative medicine, and surgery.

www.karger.com/cto

KARGER

Cardiovascular Regenerative Biology

Editors: Badylak, S.F. (Pittsburgh, Pa.); Hirschi, K.K.; Niklason, L.E. (New Haven, Conn.)

184 p., 73 fig., 33 in color, 5 tab., soft cover, 2012
CHF 52. – EUR 43. – USD 61.00

Contents

Preface

Cardiovascular Regenerative Biology:

Badylak, S.F.; Hirschi, K.K.; Niklason, L.E.

Cell Sources for Cardiovascular Tissue

Derivation of Smooth Muscle Cells with Neural Crest Origin from Human Induced Pluripotent Stem Cells: Wang, A.; Tang, Z.; Li, X.; Jiang, Y.; Tsou, D.A.; Li, S.

Smooth Muscle and Other Cell Sources for Human Blood Vessel Engineering: Sundaram, S.; Niklason, L.E.

Methods of Cell Purification: A Critical Juncture for Laboratory Research and Translational Science: Amos, P.J.; Cagavai Bozukulak, E.; Qyang, Y.


Niche Scaffolds


Blood Vessels and Vascular Networks

How Blood Vessel Networks Are Made and Measured: Chappell, J.C.; Wiley, D.M.; Bautch, V.L.


Molecular Mechanisms Controlling Vascular Lumen Formation in Three-Dimensional Extracellular Matrices: Sacharidou, A.; Stratman, A.N.; Davis, G.E.


Engineered Heart Tissue


Optimizing Dynamic Interactions between a Cardiac Patch and Inflammatory Host Cells: Freytes, D.O.; Santambrogio, L.; Vunjak-Novakovic, G.

Please send: ___ copy/ies

Postage and handling free with prepaid payment

Payment:

- Please charge to my credit card
  - American Express
  - Diners
  - MasterCard
  - Visa

Card No.: ___

Exp. date: ___

CWW/VOC

(3 digits in the signature field on the back of Visa and MasterCard)

- Check enclosed
- Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Payment:}

American Express
Diners
MasterCard
Visa

Card No.: ___
Exp. date: ___

Name:

Address:

Date:

Signature:

Fax: +41 61 306 12 34
S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
E-Mail orders@karger.ch, www.karger.com
Contents

Foreword
Preface

Updated Clinical Classification of Pulmonary Hypertension: Montani, D.; Simonneau, G.
Pathology of Pulmonary Arterial Hypertension: Dorfmüller, P.


Exercise Testing in Pulmonary Arterial Hypertension: Provencher, S.; Mainguy, V.
Noninvasive Exploration of the Pulmonary Circulation and the Right Heart: Vonk Noordegraaf, A.; Peacock, A.; Naeije, R.

Biomarkers in Pulmonary Arterial Hypertension: Souza, R.; Hoette, S.; Dias, B.; Jardim, C.

Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension: Girerd, B.; Montani, D.; Yaici, A.; Eyries, M.; Coulet, F.; Soubrier, F.; Humbert, M.

Drug- and Toxin-Induced Pulmonary Arterial Hypertension: Price, L.; Bouillon, K.; Wort, S.J.; Humbert, M.

Pulmonary Vascular Disorders

Editors
Marc Humbert
Rogério Souza
Gérald Simonneau

An excellent overview of recent advances in diagnosis, classification and treatment

Pulmonary Vascular Disorders

Humbert, M.

Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries: Jiang, X.; Humbert, M.; Jing, Z.-C.
Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders: Le Pavec, J.; Hassoun, P.M.
Pulmonary Arterial Hypertension and HIV and Other Viral Infections: Degano, B.; Valmury, S.; Sitbon, O.; Humbert, M.

Portopulmonary Hypertension and Hepatopulmonary Syndrome: Savale, L.; Hervé, P.; Sitbon, O.
Pulmonary Hypertension in Congenital Heart Diseases: Tissot, C.; Begetti, M.
Pulmonary Hypertension in Sickle Cell Disease: Parent, F.; Savale, L.; Maître, B.; Simonneau, G.

Pulmonary Veno-Occlusive Disease: Montani, D.; Huertas, A.; Dorfmüller, P.; Humbert, M.
Pulmonary Hypertension and Left Heart Disease: Adir, Y.; Galie, N.
Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Weitzenblum, E.

Choocut, A.; Canvet, M.; Duclon, A.; Kessler, R.
Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases: Nunes, H.; Uzunhan, Y.; Gille, T.; Dauriat, G.; Brauner, M.; Kambouchner, M.; Valeyre, D.
High-Altitude Pulmonary Hypertension: Di, R.-M.; Jing, Z.-C.
Acute Pulmonary Venous Thromboembolic Disease: Sanchez, O.; Meyers, G.
Anticoagulation for Venous Thromboembolism in the Modern Management Era: Le Gal, G.; Leroyer, C.; Mattier, D.

Chronic Thromboembolic Pulmonary Hypertension: Lang, I.M.; Jais, X.
Medical Treatment of Pulmonary Arterial Hypertension: O’Callaghan, D.S.; Gaine, S.P.
Lung Transplantation and Role for Novel Extracorporeal Support in Pulmonary Hypertension: Hoeper, M.M.

Atrial Septostomy: Vachiéry, J.-L.
Pulmonary Vascular Disorders in Hereditary Hemorrhagic Telangiectasia: Cottin, V.; Khouatra, C.; Dupuis-Girod, S.; Cordier, J.-F.
Future Perspectives in Pulmonary Arterial Hypertension: Rubin, L.J.

Author and Subject Index
Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Antiplatelet and anticoagulant therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes. With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers. The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.

Contents

Introduction: Serebruany, V.L.; Atar, D.
Impact of Antiplatelet Therapy in Heart Disease: Renda, G.; de Caterina, R.
Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: Aspirin: Tanguay, J.-F.
Clopidogrel in Coronary Artery Disease: Update 2012: Huber, K.
Prasugrel: Tello-Montoliu, A.; Tomasello, S.D.; Angiolillo, D.J.
Antiplatelet Therapy in Acute Coronary Syndromes: Ticagrelor: Husted, S.
Dipyridamole in Antithrombotic Treatment: Eisert, W.G.
Protease-Activated Receptor-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary Syndrome: Leonardi, S.; Tricoci, P.; Becker, R.C.
Genetic Considerations: Price, M.J.
Stents and Antiplatelet Therapy: Fassa, A.-A.; Urban, P.

Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation: Vavalle, J.P.; Rao, S.V.
Challenges in Atrial Fibrillation: Pisters, R.; ten Cate, H.; Crijns, H.J.
Conclusion: Atar, D.; Serebruany, V.L.